Explore PMI Science, where innovation meets harm reduction. Learn about our scientists, smoke-free research, and commitment to transparency in research.
PMI offers smoke-free alternatives with the potential to reduce the risk of harm for adult smokers who do not quit. Learn about harm reduction, the role of nicotine, and the regulation of smoke-free products.
Discover PMI's rigorous scientific approach to smoke-free products and product assessment. Dive into our research results, peer-reviewed publications, independent research, and expert reports.
PMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.
Explore the latest insights and stay informed about upcoming events and conference presentations from PMI scientists.
Ask a question or send us feedback. We're happy to answer.
Explore PMI Science, where innovation meets harm reduction. Learn about our scientists, smoke-free research, and commitment to transparency in research.
PMI offers smoke-free alternatives with the potential to reduce the risk of harm for adult smokers who do not quit. Learn about harm reduction, the role of nicotine, and the regulation of smoke-free products.
Discover PMI's rigorous scientific approach to smoke-free products and product assessment. Dive into our research results, peer-reviewed publications, independent research, and expert reports.
PMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.
Explore the latest insights and stay informed about upcoming events and conference presentations from PMI scientists.
Ask a question or send us feedback. We're happy to answer.
Roemer, E.; H-Roethig, H-J. Roethig.; H-Haussmann, H-J. Haussmann.
Eight conventional U.S. market cigarettes, representing a cross-section of design parameters, two blended reference cigarettes, and an electrically heated prototype cigarette (EHC) were machine-smoked under US Federal Trade Commission conditions and Massachusetts DPH conditions. Smoke was evaluated for chemical composition and in vitro toxicity. Theoretical risk estimates were calculated using a model based on the U.S. EPA approach for chemical mixtures. Regression curves were fitted to the data from the market cigarettes to investigate potential relationships. Puffing profiles for two of the market cigarettes and the EHC were determined in humans; smoke generated under these conditions was evaluated for the same endpoints. Generally, the yields of individual smoke constituents, in vitro toxicity, and theoretical risk estimates per cigarette increased with increasing yields of total particulate matter (TPM), but the increase was less than proportional. These relationships could be described well by non-linear regression. For example, when increasing the TPM yield by a factor of 4 (range: 5 to 20 mg/cigarette), the bacterial mutagenicity in strain ta100 increased by a factor of 3.1, i.e., 22% less than proportional. On average, the increases in smoke constituent yields, in vitro toxicity, and theoretical risk estimates were 15% less than proportional in this range, irrespective of whether the increased TPM yields were due to smoking conditions or cigarette construction. This analysis indicates that at the same TPM yield, the smoke constituent yields, in vitro toxicity, and theoretical risk estimates per cigarette were similar for low and high yield cigarettes. The two market cigarettes, when machine-smoked using human puffing profiles, and the reference cigarettes fitted fairly well to these relationships, supporting the data interpretation. The EHC was consistently approximately 90% lower in all endpoints as regression analysis for conventional cigarettes would suggest.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.